Capricor Therapeutics (CAPR) vs Rezolute (RZLT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Capricor Therapeutics (CAPR) has outperformed Rezolute (RZLT) over the past year, gaining 7.1% versus a loss of 46.8%. Over five years, CAPR leads with a +102.3% price change compared with -30.2% for RZLT. Capricor Therapeutics is the larger company by market cap ($460.5 million vs $442.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CAPR | RZLT |
|---|---|---|
| Share price | $7.92 | $4.57 |
| Market cap | $460.46M | $442.41M |
| 1-day change | -1.12% | -1.42% |
| YTD return | -72.25% | +96.61% |
| 1-year return | +7.09% | -46.79% |
| 5-year return | +102.27% | -30.23% |
| EPS (TTM) | $-2.45 | $-0.75 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $40.37 | $11.46 |
| 52-week low | $2.96 | $1.07 |
| Distance from 52-week high | -80.38% | -60.08% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +240.91% | +114.25% |
| Average volume | 6.87M | 1.50M |
| Shares outstanding | 58.14M | 96.72M |
| Employees | 231 | 58 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CAPR has outperformed RZLT by 53.9 percentage points over the past year.
About Capricor Therapeutics
CAPR stock →Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD.
Health Care · Biotechnology: Pharmaceutical Preparations · 231 employees
About Rezolute
RZLT stock →Rezolute, Inc., a late-stage rare disease company, focuses developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism (HI) in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody which is in Phase 3 clinical trial to treat tumor HI indication, as well as congenital HI.
Health Care · Biotechnology: Pharmaceutical Preparations · 58 employees
CAPR vs RZLT FAQ
Which is bigger, Capricor Therapeutics or Rezolute?
Capricor Therapeutics (CAPR) is larger, with a market capitalization of $460.46M compared with $442.41M for Rezolute (RZLT).
Which stock has performed better over the past year, CAPR or RZLT?
CAPR returned +7.09% over the past 12 months, compared with -46.79% for RZLT (price return, excluding dividends). Past performance does not predict future results.
Are Capricor Therapeutics and Rezolute in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.